Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Biomarker Assessment of Pomaglumetad on Glutamate Targets: Proof of Clinical Mechanism of Action (POCM)


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT02919774

Organisation Name: New York State Psychiatric Institute

Overal Status: Completed

Start Date: October 2016

Last Update: September 12, 2018

Lead Sponsor: New York State Psychiatric Institute

Brief Summary: The study will evaluate the effects of the mGluR2/3 partial agonist LY2140023 (Pomaglumetad Methionil, "POMA") at selected doses on ketamine-stimulated glutamate release in prefrontal cortex as measured by pharmacoBOLD fMRI (also termed resting BOLD fMRI).

Conditions:
  • Healthy Controls


Total execution time in seconds: 0.14545607566833